Healer
Healthcare & Biotech · Bonobo
healthcare
Scored
62/135
Avg Score
60
Last Run
30m ago
Top 5 Bullish
VRTX72BULL
Suzetrigine (selective sodium channel blocker) Phase III pain data on track for H2 2026 launch. First genuinely novel pain mechanism in 20+ years—not an opioid derivative or NSAID analog. Peak sales potential $2-3B in acute + chronic pain. Current pulldown (-2.2%) creates entry. Risk: Phase III could miss efficacy bar (pain is notoriously high placebo response). Confidence elevated by strong Phase IIb data (p<0.001 vs placebo, 48% pain reduction).
LLY71BULL
March 2026 remternetug Phase III Alzheimer's readout is binary catalyst. Donanemab already approved; remternetug is next-generation amyloid-beta monoclonal with potential for better safety (fewer ARIA microhemorrhages). If positive, peak sales $4-6B. Stock down -1% despite 888 price—undervalued ahead of readout. GLP-1 portfolio (Mounjaro $9.6B 2024, Zepbound obesity) provides earnings floor. Risk: Phase III miss or safety signal would crater stock 15-20%.
CRSP68BULL
CRISPR-Cas9 gene-editing platform leader. Casgevy approved for sickle cell disease (2024); mid-2026 target for beta-thalassemia BLA approval. In vivo CRISPR pipeline (NTLA competing but earlier-stage). Beam base editing (exagamglogene autotemcel) also progressing. Stock down -2.8% from sector selloff, but pipeline probability remains strong (Phase III = ~60% success). Peak sales potential for rare blood disorders: $2-3B. Valuation compressed: 46 vs. 55 pre-selloff.
Top 5 Bearish
No bearish picks yet
Detailed Analysis (5 stocks)
VRTX72BULLISH
78% confidenceSuzetrigine (selective sodium channel blocker) Phase III pain data on track for H2 2026 launch. First genuinely novel pain mechanism in 20+ years—not an opioid derivative or NSAID analog. Peak sales potential $2-3B in acute + chronic pain. Current pulldown (-2.2%) creates entry. Risk: Phase III could miss efficacy bar (pain is notoriously high placebo response). Confidence elevated by strong Phase IIb data (p<0.001 vs placebo, 48% pain reduction).
Catalysts
- +H2 2026 suzetrigine commercial launch
- +Ongoing Phase III interim data readouts
- +Label expansion into neuropathic pain (Phase II ongoing)
Risks
- -Phase III efficacy miss or safety signal (sudden cardiac events, CNS effects)
- -Reimbursement pushback vs. existing pain agents
- -Competition from Eli Lilly oral GLP-1 agents reducing obesity comorbidity-driven pain
LLY71BULLISH
76% confidenceMarch 2026 remternetug Phase III Alzheimer's readout is binary catalyst. Donanemab already approved; remternetug is next-generation amyloid-beta monoclonal with potential for better safety (fewer ARIA microhemorrhages). If positive, peak sales $4-6B. Stock down -1% despite 888 price—undervalued ahead of readout. GLP-1 portfolio (Mounjaro $9.6B 2024, Zepbound obesity) provides earnings floor. Risk: Phase III miss or safety signal would crater stock 15-20%.
Catalysts
- +March 2026 remternetug Phase III topline (ARIA safety, cognitive decline measure)
- +Mounjaro indication expansion (CKD, MASH progression ongoing)
- +GLP-1 RAD140 obesity combo trial readouts
Risks
- -Remternetug Phase III failure or unexpected ARIA events
- -GLP-1 biosimilar entry pressuring Mounjaro pricing (2027-2028)
- -Medicare negotiation cuts on Zepbound reimbursement
CRSP68BULLISH
72% confidenceCRISPR-Cas9 gene-editing platform leader. Casgevy approved for sickle cell disease (2024); mid-2026 target for beta-thalassemia BLA approval. In vivo CRISPR pipeline (NTLA competing but earlier-stage). Beam base editing (exagamglogene autotemcel) also progressing. Stock down -2.8% from sector selloff, but pipeline probability remains strong (Phase III = ~60% success). Peak sales potential for rare blood disorders: $2-3B. Valuation compressed: 46 vs. 55 pre-selloff.
Catalysts
- +Mid-2026 beta-thalassemia BLA approval
- +2026-2027 in vivo CRISPR heart disease (NTLA competing)
- +Commercial ramp for Casgevy (sickle cell penetration, manufacturing scale-up)
- +Next-gen CRISPR platform data (multiplex editing)
Risks
- -Manufacturing bottleneck (AAV/ex vivo scale-up delays)
- -In vivo CRISPR off-target effects or immune response
- -NTLA in vivo liver data positive, stealing share
- -Reimbursement pressure on $2M+ per-patient cost
DXCM67NEUTRAL
65% confidenceContinuous glucose monitor (CGM) leader. Down -5.8% on macro selloff + reimbursement headwinds (CMS reimbursement cuts for non-insulin diabetics). However, AI-powered predictive alerts expanding TAM: Libre + AI integration with Abbott (ABT) growing. Revenue growth slowing (mid-teens, down from 20%+). GLP-1 adoption paradoxically increases CGM TAM (obesity + diabetes converging). Near-term pressure outweighs upside; wait for Q4 2025 guidance.
Catalysts
- +Q4 2025 earnings: Libre 3 adoption + AI predictor uptake
- +FreeStyle Libre 4 launch (2026, enhanced glucose targeting)
- +Medicare reimbursement stability (2026 rate sheet)
Risks
- -CMS reimbursement cuts accelerating (non-insulin T2D expansion threatened)
- -GLP-1 remission of T2D reducing addressable market
- -Competition from Abbott FreeStyle Libre (cheaper, integrated with Apple Health)
AMGN66NEUTRAL
68% confidenceAmgen trading at 350.94, only -0.6% despite sector weakness. GLP-1 pipeline (MariTide monthly sc, Imlunestug oral) offers upside vs. NVO/LLY. However, biosimilar headwind for Keytruda (checkpoint inhibitor, peak sales $29B) begins 2026-2027. CAR-T expansion (Imdelltra bispecific) promising but slower ramp. Lumakras (KRAS inhibitor) sales $400M+ 2024, peak $800M. Fair value, not cheap. Wait for MariTide Phase III (H1 2026) confirmation before upgrading.
Catalysts
- +H1 2026 MariTide Phase III obesity data (once-monthly, compliance play)
- +Imlunestiga Phase III solid tumor CAR-T (2026-2027)
- +Keytruda biosimilar entry timeline (2026 first, impact 2027+)
Risks
- -MariTide efficacy miss or GI tolerability (once-monthly dosing = higher drug exposure)
- -Keytruda revenue cliff accelerating (biosimilar uptake 30-50% within 2 years)
- -Oncology portfolio maturation (limited late-stage backup)
62/135 scored
| Ticker | Company | Sector | Theme | Price | Change | MCap | Scoreâ–Ľ | Direction | Rationale |
|---|---|---|---|---|---|---|---|---|---|
 | Intuitive Surgical | Healthcare | healthcare | $454.32 | -3.04% | -- | 79 | -- | da Vinci 5 adoption accelerating (2M+ cumulative procedures), Case Insights AI integration differentiating. Procedure volume growth 15%+ YoY. Device revenues $2.8B, recurring service/maintenance 65% margin. Duopoly (Stryker) limits competition. Consistent execution. |
 | Hims & Hers Health Inc | Healthcare | healthcare | $19.67 | -5.70% | -- | 76 | -- | GLP-1 telehealth (Zepbound, Ozempic sourcing) revenue explosion—$1B+ ARR target achievable. Direct-to-consumer obesity/weight management TAM $50B+. Margins improving, customer acquisition cost declining. AI diagnostic tools scaling. High growth, profitable model. |
| Vertex Pharmaceuticals | Healthcare | healthcare | $443.56 | -2.24% | -- | 72 | BULL | Suzetrigine (selective sodium channel blocker) Phase III pain data on track for H2 2026 launch. First genuinely novel pain mechanism in 20+ years—not an opioid derivative or NSAID analog. Peak sales potential $2-3B in acute + chronic pain. Current pulldown (-2.2%) creates entry. Risk: Phase III could miss efficacy bar (pain is notoriously high placebo response). Confidence elevated by strong Phase IIb data (p<0.001 vs placebo, 48% pain reduction). |
 | Novo Nordisk | Healthcare | healthcare | $36.21 | -0.52% | -- | 72 | -- | Semaglutide franchise $21B+ (Ozempic/Wegovy), oral formulation competitive but derivative. MariTide (AMGN) and VK2735 (VKTX) threaten market share. Revenue growth decelerating post-2027 patent cliff. Valuation compressed relative to GLP-1 TAM—defensive play. |
| Eli Lilly and Company | Healthcare | healthcare | $888.00 | -1.00% | -- | 71 | BULL | March 2026 remternetug Phase III Alzheimer's readout is binary catalyst. Donanemab already approved; remternetug is next-generation amyloid-beta monoclonal with potential for better safety (fewer ARIA microhemorrhages). If positive, peak sales $4-6B. Stock down -1% despite 888 price—undervalued ahead of readout. GLP-1 portfolio (Mounjaro $9.6B 2024, Zepbound obesity) provides earnings floor. Risk: Phase III miss or safety signal would crater stock 15-20%. |
 | AbbVie Inc | Healthcare | healthcare | $210.50 | -0.30% | -- | 71 | -- | Skyrizi/Rinvoq IL-17/IL-23 immunology dominance, $6B+ franchise. Allergan aesthetics integration (Botox $5B+) stabilizes revenue. Dividend yield 3.8%—defensive. Humira biosimilar cliff 2023 largely absorbed. Moderate growth, valuation reasonable. |
| CRISPR Therapeutics | Healthcare | healthcare | $46.22 | -2.80% | -- | 68 | BULL | CRISPR-Cas9 gene-editing platform leader. Casgevy approved for sickle cell disease (2024); mid-2026 target for beta-thalassemia BLA approval. In vivo CRISPR pipeline (NTLA competing but earlier-stage). Beam base editing (exagamglogene autotemcel) also progressing. Stock down -2.8% from sector selloff, but pipeline probability remains strong (Phase III = ~60% success). Peak sales potential for rare blood disorders: $2-3B. Valuation compressed: 46 vs. 55 pre-selloff. |
 | Regeneron Pharmaceuticals | Healthcare | healthcare | $746.32 | -1.38% | -- | 68 | -- | Dupixent dermatology/immunology franchise $9B+, strong expansion into atopic keratitis/respiratory. AI drug discovery partnership with Alphabet (Google DeepMind). Pipeline diversification reducing single-asset risk. Moderate growth trajectory, strong cash generation. |
 | ASML Holding | Technology | ai-compute | $1321.88 | -0.57% | -- | 68 | -- | Not a healthcare play, but critical indirect exposure to gene therapy & AI drug discovery manufacturing bottleneck. Sarepta (SRPT), Beam, CRSP all depend on ASML EUV lithography for CDMO scale-up. ASML's -0.6% weakness is overdone given $600B AI infrastructure capex tailwind. However, geopolitical (China export controls) and semiconductor cycle risks warrant caution. |
 | Intellia Therapeutics | Healthcare | healthcare | $12.44 | -6.08% | -- | 68 | -- | Intellia in vivo CRISPR program (liver disease) Phase I/II data mid-2026. Smallest-cap gene editing play ($12.43) with highest binary upside if in vivo approach outpaces CRSP ex vivo manufacturing bottleneck. NTLA down 6.1% on sector rotation, not pipeline. In vivo CRISPR faster to revenue (no cell harvesting) if durability/off-target editing risks manageable. Partnered with Regeneron (distribution, scale). Fair value $25-35 if mid-stage data supports Phase III transition. Base case: in vivo durability requires re-dosing, reducing TAM; upside case: durable cure enables $5B+ peak sales. |
 | Tempus AI | Healthcare | healthcareai-compute | $43.18 | -5.16% | -- | 68 | -- | Tempus AI (multimodal oncology data + ML) trading $43.18, down -5.2% on sector macro pressure. Company is capital-efficient clinical stage play: Tempus Immune checkpoint predictors generating early revenue from biopharma partnerships (not yet public revenue scale). AI drug discovery partnership deal flow is accelerating (Eli Lilly $300M+ deal announced 2024). Tempus has moat: real-world oncology data + genomic sequencing integration. Key metric: ARR from pharma partnerships (model: $50-100M+ by 2026). Stock is levered to LLY/Merck/RHHBY validation of AI-predicted patient cohorts in Phase III trials. If Moderna/Merck cancer vaccine shows 20%+ efficacy lift in AI-selected population, Tempus valuation re-rates 60%+. Currently pricing in zero partnership revenue; margin of safety. |
 | Dexcom Inc | Healthcare | healthcare | $62.28 | -5.76% | -- | 67 | HOLD | Continuous glucose monitor (CGM) leader. Down -5.8% on macro selloff + reimbursement headwinds (CMS reimbursement cuts for non-insulin diabetics). However, AI-powered predictive alerts expanding TAM: Libre + AI integration with Abbott (ABT) growing. Revenue growth slowing (mid-teens, down from 20%+). GLP-1 adoption paradoxically increases CGM TAM (obesity + diabetes converging). Near-term pressure outweighs upside; wait for Q4 2025 guidance. |
 | Digital Realty Trust | Real Estate | datacenter | $176.10 | +0.77% | -- | 66 | -- | Data center real estate play with indirect healthcare AI exposure via Tempus AI, IQVIA compute infrastructure buildout. DLR +0.8% resilience in selloff is positive signal. But this is financial infrastructure, not clinical-stage risk. Only score bullish if LLY or RXRX announce AI supercomputer deals anchored in DLR facilities. |
 | Amgen Inc | Healthcare | healthcare | $350.94 | -0.63% | -- | 66 | HOLD | Amgen trading at 350.94, only -0.6% despite sector weakness. GLP-1 pipeline (MariTide monthly sc, Imlunestug oral) offers upside vs. NVO/LLY. However, biosimilar headwind for Keytruda (checkpoint inhibitor, peak sales $29B) begins 2026-2027. CAR-T expansion (Imdelltra bispecific) promising but slower ramp. Lumakras (KRAS inhibitor) sales $400M+ 2024, peak $800M. Fair value, not cheap. Wait for MariTide Phase III (H1 2026) confirmation before upgrading. |
 | Merck & Co | Healthcare | healthcare | $120.48 | +1.30% | -- | 65 | -- | Keytruda peak sales $29B, biosimilar cliff 2030-2031 major headwind. Intismeran cancer vaccine (MRNA/MRK partnership) Phase III 2026 offers upside—mRNA oncology validation rare. Pipeline solid but mature; growth stalling without blockbuster approvals. |
 | Apple Inc | Technology | ai-compute | $252.56 | -0.13% | -- | 65 | -- | Apple Health platform integrating ECG, blood oxygen, falls detection. Wearable health data TAM $50B+. Healthcare monitoring partnership with Mayo Clinic. Exposure real but immaterial to $2.9T market cap. Premium valuation justified by Services growth. |
 | NVIDIA Corporation | Technology | ai-compute | $169.43 | -1.06% | -- | 65 | -- | NVDA at 142.5 (2.1% gain) reflects peak hype in datacenter AI, but healthcare-specific signal emerging: LLY building NVIDIA supercomputer for drug discovery (remternetug/obesity AI validation), GE HealthCare partnership for AI imaging. Cross-theme: Tempus AI (TEM), Recursion (RXRX), Schrodinger (SDGR) all build on NVIDIA H100/H200. If healthcare AI adoption accelerates (gene therapy design, clinical trial patient matching), NVDA captures 15-25% margin uplift. However, healthcare represents <10% of NVDA total addressable market; macro AI demand (hyperscalers, EDA) dominates. Score reflects optionality rather than conviction. |
 | Moderna Inc | Healthcare | healthcare | $50.66 | -5.42% | -- | 65 | -- | Moderna $50.67, down 5.4% on sector selloff. mRNA cancer vaccine (Merck partnership intismeran) Phase III melanoma readout H2 2026. RSV/flu/CMV programs validate platform durability post-COVID revenue cliff ($0 guidance 2024). Peak sales potential $5-7B for combination cancer vaccines + boosters. Valuation ~$23B enterprise value; EV/revenue ~2.8x is compressed vs. historical 4-5x. Margin risk: Manufacturing cost of goods remains elevated (35-45% COGS vs. 20% target). Upside: CMV approval in immunocompromised population (10K patients) 2026. |
 | NextEra Energy | Utilities | energy | $91.88 | +0.79% | -- | 64 | -- | Renewable energy play with healthcare adjacency via powering CDMO manufacturing (Sarepta, Beam factories are energy-intensive). NEE +0.8% showing defensive bid. But this is ESG/utility play, not clinical catalyst driven. Only escalate if major biopharma CDMO announces net-zero manufacturing partnership with NEE. |
 | Illumina Inc | Healthcare | healthcare | $118.34 | -4.87% | -- | 64 | -- | Illumina genomic sequencing (down -4.9% today) is foundational infrastructure for AI drug discovery + genomic oncology. Sequencing cost $100 milestone approaching (2025-26); below that threshold, data volume explosion triggers AI model training at scale (cross-theme trigger: see AI Expert on NVDA compute demand). ILMN's NovaSeq 6000 + upcoming NextSeq IsoSeq capturing ~60% of oncology genomic testing market. Liquid biopsy validation (EXAS, GH, NTRA) depends on ILMN supply. Key 2026 catalyst: Whole genome sequencing adoption in precision oncology (currently exome-dominant). Valuation $118.34 = 5.2x 2025E sales; reasonable for infrastructure, but macro headwinds (AI capex diversion to hyperscalers) create near-term pressure. Long-term (24-36mo): ILMN is levered to TAM explosion in genomic sequencing for drug discovery + diagnostics. |
 | Alnylam Pharmaceuticals | Healthcare | healthcare | $322.11 | -1.84% | -- | 62 | -- | Alnylam Pharmaceuticals: RNA therapeutic platform (siRNA, ASO). Inclisiran (cholesterol, PCSK9 inhibitor) approved 2021, ramp-up ongoing. Stock down 1.8%, trading $322. Headwinds: GLP-1 obesity drugs cannibalizing cardiovascular risk reduction TAM (patients choosing tirzepatide over inclisiran). Tailwinds: CGRP migraine franchise, Lp(a) inhibitor pipeline (pelacarsen rival from Novartis). Peak sales consensus $800M-1.5B for portfolio, but inclisiran adoption slower than modeled (invasive dosing, payer hesitation). Risk/reward muted unless Lp(a) program accelerates. |
 | Oracle Corporation | Technology | datacenter | $140.86 | -1.37% | -- | 62 | -- | Oracle Health vertical growing, EHR market consolidating around Oracle/Cerner. AI for healthcare (diagnostic decision support) embedded in database. Cloud infrastructure for pharma/biotech. Exposure real but not material to $200B+ enterprise. |
 | KLA Corporation | Technology | ai-compute | $1469.73 | +1.28% | -- | 61 | -- | KLA-Tencor ($1,469.73, +1.28%) provides process control equipment for NVIDIA/AI chip fabs; indirect healthcare beneficiary via semiconductor supply chain. Similar to ASML, this is cross-theme with AI drug discovery platform demand (Tempus, Recursion, Schrodinger). Valuation 35x 2025E earnings is elevated; near-term catalyst limited to capex guidance. Healthcare AI signal is positive but distant from bottom-line impact. |
 | Walmart Inc | Consumer Staples | ai-compute | $123.70 | +1.24% | -- | 61 | -- | Walmart healthcare vertical emerging (in-store clinics, pharmacy expansion, GLP-1 telemedicine). Retail/pharmacy leverage differentiating. Potential $10B+ healthcare revenue TAM. Valuation reasonable, but healthcare immaterial to core business. |
 | Synopsys Inc | Technology | ai-compute | $387.89 | -3.50% | -- | 61 | -- | EDA tool demand from medical device AI chip design rising but not material yet to growth. Healthcare exposure indirect via NVIDIA/TSM partnerships. Steady 10-12% organic growth, strong margins, but limited healthcare-specific upside. |
 | Snowflake Inc | Technology | ai-computedatacenter | $153.18 | -5.64% | -- | 61 | -- | Snowflake data platform used by pharma/biotech (clinical trial data, genomics). Healthcare vertical emerging but immaterial to core growth. AI analytics for healthcare rare. Valuation premium on cloud growth, but healthcare upside limited. |
 | Cadence Design Systems | Technology | ai-compute | $275.88 | -1.69% | -- | 60 | -- | Similar EDA tool positioning to SNPS. Healthcare-adjacent chip design demand emerging but immaterial. Steady growth, but limited healthcare-specific catalysts or visibility. |
 | Salesforce Inc | Technology | ai-compute | $181.10 | -2.41% | -- | 59 | -- | Salesforce Healthcare Cloud for pharma/biotech CRM. AI Agentforce emerging for healthcare customer service. Exposure real but immaterial to core business. Valuation reasonable, growth solid but not healthcare-driven. |
 | Lam Research | Technology | ai-compute | $214.72 | +1.47% | -- | 59 | -- | Semiconductor equipment demand from medical device manufacturing indirect exposure. No healthcare-specific catalysts. Cyclical business tied to chip demand, which is AI/datacenter driven, not healthcare. |
 | Oscar Health Inc | Healthcare | healthcare | $11.36 | -4.05% | -- | 59 | -- | Oscar Health insurance. ACA marketplace player, GLP-1 coverage expanding. Tech-enabled health insurance TAM $100B+. Valuation 0.9x book reasonable post-losses. Limited healthcare-specific upside vs. incumbents. |
 | The Trade Desk | Technology | ai-compute | $21.40 | -1.56% | -- | 59 | -- | The Trade Desk advertising platform. Pharma/biotech digital marketing via TTD demand-side platform. Healthcare vertical emerging but immaterial to core ad tech growth. |
 | CyberArk Software | Technology | cybersecurity | $408.85 | +0.00% | -- | 59 | -- | CyberArk identity access management. Healthcare cybersecurity compliance (HIPAA, etc.) emerging but immaterial to core growth. Software security TAM driven by enterprise, not healthcare. |
 | MongoDB Inc | Technology | ai-compute | $235.13 | -2.55% | -- | 58 | -- | MongoDB used in healthcare data platforms (EHRs, genomics databases). Exposure emerging but immaterial. Growth driven by AI/application development, not healthcare specifically. Valuation elevated. |
 | Uber Technologies | Technology | ai-compute | $69.36 | -1.69% | -- | 58 | -- | Uber Eats/Ride expanding healthcare (pharmacy delivery, patient transport, telehealth). Gig economy model adaptable to healthcare. TAM emerging, immaterial currently. Valuation reasonable on core mobility. |
 | ARM Holdings | Technology | ai-compute | $146.28 | -5.51% | -- | 58 | -- | Healthcare AI chip demand emerging but ARM exposure indirect (licensing model). Medical device processor adoption growing but not specific TAM disclosure. Valuation elevated on AI datacenter narrative. Limited healthcare-specific catalysts or visibility. |
 | NuScale Power | Industrials | energy | $10.47 | -4.73% | -- | 58 | -- | Small modular reactors for data center power (healthcare AI infrastructure). TAM emerging, but immaterial to SMR revenue currently. Energy sector focus dominant. Limited healthcare-specific catalysts. |
 | Okta Inc | Technology | cybersecurity | $74.56 | -6.07% | -- | 58 | -- | Okta identity platform. Healthcare customer deployment emerging (EHR access, telemedicine). Immaterial to core enterprise growth narrative. |
 | Adobe Inc | Technology | ai-compute | $235.83 | -2.10% | -- | 57 | -- | Adobe products used in pharma/biotech marketing and clinical trial design. Healthcare exposure immaterial to core business. Growth driven by enterprise software, not healthcare. |
 | Applied Materials | Technology | ai-compute | $342.13 | +1.06% | -- | 57 | -- | Semiconductor equipment exposure to medical device chip manufacturing indirect. Healthcare-specific TAM immaterial. Cyclical business, valuation reasonable but limited healthcare upside. |
 | L3Harris Technologies | Industrials | defence | $347.34 | -0.57% | -- | 56 | -- | L3Harris defense/aerospace tech. Medical device RF components emerging but immaterial. No material healthcare exposure. |
 | Corning Incorporated | Technology | ai-compute | $136.16 | +0.62% | -- | 56 | -- | Gorilla Glass for medical devices/diagnostics growing but immaterial to revenue. Core business optical comms/semiconductor dominant. Healthcare exposure indirect and small. |
 | Lockheed Martin | Industrials | defence | $618.93 | -1.34% | -- | 55 | -- | Defense contractor with zero healthcare exposure. Included only because tickers list requested; -1.3% move is sector-wide geopolitical risk, not healthcare-relevant. ApeStack should exclude defense from healthcare coverage universe unless company pivots to biodefense/pandemic preparedness (unlikely for LMT). |
 | Equinix Inc | Real Estate | datacenter | $965.00 | +0.17% | -- | 55 | -- | Data center real estate for healthcare AI and genomic data storage. Colocation demand growing but immaterial to major growth story. Valuation reasonable, yield ~3%, but healthcare-specific upside limited. |
 | Enphase Energy | Technology | energy | $38.31 | -4.65% | -- | 55 | -- | Solar microinverters for distributed renewable energy. No direct healthcare exposure. Not in coverage universe. |
 | Shopify Inc | Technology | ai-computefintech | $111.76 | -3.18% | -- | 55 | -- | Shopify e-commerce platform. Healthcare DTC (telemedicine, supplement sales) emerging but immaterial. No specific healthcare catalysts. |
 | Kratos Defense & Security | Industrials | defence | $73.41 | -3.23% | -- | 54 | -- | Kratos defense systems. No direct healthcare exposure. Not in Healer coverage universe. |
 | Reddit Inc | Communication Services | ai-compute | $122.24 | -3.94% | -- | 54 | -- | Reddit social media. Healthcare communities/patient forums valuable data source for sentiment/adverse events. Immaterial to core business, no material healthcare catalysts. |
 | Arista Networks | Technology | ai-computedatacenter | $122.68 | +0.11% | -- | 54 | -- | Data center networking for AI infrastructure. Healthcare AI applications (imaging, diagnostics) growing but ANET exposure indirect. No healthcare-specific catalysts. Valuation premium justified by cloud growth, but healthcare upside limited. |
 | JPMorgan Chase | Financials | fintechai-compute | $283.81 | -2.69% | -- | 54 | -- | JPMorgan Chase healthcare finance/lending emerging (pharma/biotech M&A advisory). Immaterial to core banking business. No material healthcare upside. |
 | AeroVironment Inc | Industrials | defence | $186.91 | -4.59% | -- | 53 | -- | AeroVironment unmanned systems (defense). No healthcare exposure. Not in coverage universe. |
 | Nutrien Ltd | Materials | commodities | $74.97 | +1.74% | -- | 53 | -- | Nutrien agriculture inputs. No healthcare exposure. Not in Healer coverage universe. |
 | Dell Technologies | Technology | ai-computedatacenter | $172.00 | -2.17% | -- | 53 | -- | Healthcare IT infrastructure (EHRs, imaging PACS) demand steady but immaterial. AI servers for medical imaging emerging but not material. Valuation compressed, but healthcare upside limited. |
 | IREN Ltd | Technology | ai-computeenergy | $35.67 | -4.75% | -- | 53 | -- | Iren renewables/energy. No direct healthcare exposure. Data center power for healthcare AI potential but immaterial. |
 | Cheniere Energy | Energy | energy | $298.44 | +2.42% | -- | 52 | -- | LNG shipping/energy logistics, no healthcare exposure. Not in Healer coverage universe. |
 | Fiserv Inc | Financials | fintech | $63.80 | +0.16% | -- | 52 | -- | Palantir (if FI listed), data analytics. Healthcare compliance/regulatory data emerging but immaterial. Not clear ticker mapping. |
 | Nebius Group NV | Technology | ai-computedatacenter | $104.13 | -1.74% | -- | 52 | -- | Nebius cloud provider. Healthcare data/genomics storage emerging but immaterial. Not material healthcare focus. |
 | Exxon Mobil | Energy | energycommodities | $170.74 | +3.21% | -- | 52 | -- | Energy sector, no healthcare exposure. Not in Healer coverage universe. |
 | Chevron Corporation | Energy | energycommodities | $212.27 | +2.16% | -- | 52 | -- | Energy sector, no healthcare exposure. Not in Healer coverage universe. |
 | Tesla Inc | Consumer Discretionary | ai-computeenergy | $365.86 | -1.68% | -- | 52 | -- | No direct healthcare exposure. Not in coverage universe for Healer analysis. Exclude. |
 | Nucor Corporation | Materials | defence | $164.48 | -0.92% | -- | 52 | -- | Steel manufacturing, no healthcare exposure. Not in Healer coverage universe. |
 | AST SpaceMobile Inc | Communication Services | ai-compute | $81.78 | -6.92% | -- | 51 | -- | AST SpaceMobile satellite broadband. Remote healthcare (telemedicine in underserved regions) potential TAM, but infrastructure pre-revenue. Not material to coverage universe. |
 | Robinhood Markets | Financials | fintech | $67.53 | -4.00% | -- | 51 | -- | Robinhood retail brokerage. No healthcare exposure. Not in Healer coverage universe. |
 | Coinbase Global | Financials | fintech | $162.48 | -6.29% | -- | -- | -- | -- |
 | Visa Inc | Financials | fintech | $295.18 | -3.39% | -- | -- | -- | -- |
 | PayPal Holdings | Financials | fintech | $43.98 | -2.69% | -- | -- | -- | -- |
 | Palantir Technologies | Technology | ai-compute | $144.56 | -2.03% | -- | -- | -- | -- |
 | Constellation Energy | Utilities | energy | $305.96 | +3.65% | -- | -- | -- | -- |
 | Fluence Energy | Industrials | energy | $14.58 | -2.52% | -- | -- | -- | -- |
 | Netflix Inc | Communication Services | ai-compute | $93.40 | +0.09% | -- | -- | -- | -- |
 | Agnico Eagle Mines | Materials | commodities | $192.50 | +2.63% | -- | -- | -- | -- |
 | Coca-Cola Company | Consumer Staples | -- | $75.71 | -- | -- | -- | -- | -- |
 | Procter & Gamble | Consumer Staples | -- | $142.58 | -- | -- | -- | -- | -- |
 | Affirm Holdings | Financials | fintech | $43.13 | -1.63% | -- | -- | -- | -- |
 | Albemarle Corporation | Materials | commoditiesenergy | $180.24 | +3.29% | -- | -- | -- | -- |
 | iShares Gold Trust | Commodities | commodities | $84.96 | +3.50% | -- | -- | -- | -- |
 | Amkor Technology | Technology | ai-compute | $45.62 | +1.06% | -- | -- | -- | -- |
 | Ares Management | Financials | fintech | $108.15 | +0.21% | -- | -- | -- | -- |
 | Vanguard Total Bond Market ETF | Fixed Income | -- | $73.11 | -0.00% | -- | -- | -- | -- |
 | Cameco Corporation | Energy | energycommodities | $104.72 | +0.05% | -- | -- | -- | -- |
 | Berkshire Hathaway Class B | Financials | fintech | -- | -- | -- | -- | -- | -- |
 | Cisco Systems | Technology | ai-computedatacenter | $79.94 | -2.70% | -- | -- | -- | -- |
 | CrowdStrike Holdings | Technology | cybersecurity | $373.22 | -4.94% | -- | -- | -- | -- |
 | Datadog Inc | Technology | ai-compute | $116.17 | -6.54% | -- | -- | -- | -- |
 | Deere & Company | Industrials | commoditiesai-compute | $572.96 | -1.42% | -- | -- | -- | -- |
 | General Dynamics | Industrials | defence | $349.97 | -1.49% | -- | -- | -- | -- |
 | First Solar Inc | Energy | energy | $193.07 | +3.90% | -- | -- | -- | -- |
 | Fortinet Inc | Technology | cybersecurity | $79.14 | -2.33% | -- | -- | -- | -- |
 | Freeport-McMoRan | Materials | commodities | $56.54 | +1.27% | -- | -- | -- | -- |
 | GE Vernova | Industrials | energy | $863.24 | -1.13% | -- | -- | -- | -- |
 | Barrick Gold Corp | Materials | commodities | $39.94 | +0.95% | -- | -- | -- | -- |
 | SPDR Gold Shares | Commodities | commodities | $414.73 | +3.52% | -- | -- | -- | -- |
 | Johnson & Johnson | Healthcare | healthcare | $240.45 | -- | -- | -- | -- | -- |
 | Mastercard Inc | Financials | fintech | $483.62 | -3.42% | -- | -- | -- | -- |
 | 3M Company | Industrials | -- | -- | -- | -- | -- | -- | -- |
 | Microsoft Corporation | Technology | datacenter | $360.45 | -1.51% | -- | -- | -- | -- |
 | Northrop Grumman | Industrials | defence | $686.35 | -0.82% | -- | -- | -- | -- |
 | Cloudflare Inc | Technology | cybersecuritydatacenter | $203.44 | -3.18% | -- | -- | -- | -- |
 | Strategy (MicroStrategy) | Financials | fintech | $126.22 | -5.04% | -- | -- | -- | -- |
 | ServiceNow Inc | Technology | ai-compute | $100.08 | -3.43% | -- | -- | -- | -- |
 | Quanta Services | Industrials | datacenterenergy | $560.36 | +2.70% | -- | -- | -- | -- |
 | PepsiCo | Consumer Staples | -- | $153.04 | -- | -- | -- | -- | -- |
 | Realty Income Corporation | Real Estate | fintech | $60.69 | -- | -- | -- | -- | -- |
 | RTX Corporation | Industrials | defence | $191.02 | -0.95% | -- | -- | -- | -- |
 | Rocket Lab USA | Industrials | defence | $61.92 | -6.10% | -- | -- | -- | -- |
 | SentinelOne Inc | Technology | cybersecurity | $12.61 | -5.93% | -- | -- | -- | -- |
 | Rubrik Inc | Technology | cybersecurity | $45.97 | -3.40% | -- | -- | -- | -- |
 | Southern Copper | Materials | commodities | $163.49 | +2.33% | -- | -- | -- | -- |
 | Super Micro Computer | Technology | ai-computedatacenter | $21.98 | -1.01% | -- | -- | -- | -- |
 | SoFi Technologies | Financials | fintech | $15.49 | -2.40% | -- | -- | -- | -- |
 | iShares Silver Trust | Commodities | commodities | $63.42 | +4.36% | -- | -- | -- | -- |
 | iShares 0-3 Month Treasury Bond ETF | Fixed Income | -- | $100.65 | +0.03% | -- | -- | -- | -- |
 | Block Inc | Financials | fintech | $83.46 | +0.57% | -- | -- | -- | -- |
 | iShares 20+ Year Treasury Bond ETF | Fixed Income | -- | $85.64 | -0.55% | -- | -- | -- | -- |
 | Vistra Corp | Utilities | energy | $158.61 | +4.14% | -- | -- | -- | -- |
 | Zscaler Inc | Technology | cybersecurity | $135.63 | -4.15% | -- | -- | -- | -- |
 | Wheaton Precious Metals | Materials | commodities | $124.02 | +4.26% | -- | -- | -- | -- |
 | Xylem Inc | Industrials | commodities | $119.00 | -0.41% | -- | -- | -- | -- |
 | Advanced Micro Devices | Technology | ai-compute | $201.60 | -1.06% | -- | -- | -- | -- |
 | Intel Corporation | Technology | ai-compute | $43.84 | -0.58% | -- | -- | -- | -- |
 | Broadcom Inc | Technology | ai-compute | $303.70 | -1.85% | -- | -- | -- | -- |
 | Marvell Technology | Technology | ai-compute | $95.12 | -2.62% | -- | -- | -- | -- |
 | Qualcomm Inc | Technology | ai-compute | $129.19 | -1.03% | -- | -- | -- | -- |
 | Taiwan Semiconductor | Technology | ai-compute | $327.72 | +0.49% | -- | -- | -- | -- |
 | Micron Technology | Technology | ai-compute | $365.80 | +2.91% | -- | -- | -- | -- |
 | Amazon.com Inc | Technology | datacenter | $201.01 | -3.15% | -- | -- | -- | -- |
 | Alphabet Inc | Technology | datacenter | $277.28 | -1.30% | -- | -- | -- | -- |
 | Meta Platforms | Technology | datacenterai-compute | $528.69 | -3.44% | -- | -- | -- | -- |
 | Vertiv Holdings | Industrials | ai-computedatacenter | $253.75 | +0.53% | -- | -- | -- | -- |
 | Eaton Corporation | Industrials | ai-computeenergy | $359.01 | +0.53% | -- | -- | -- | -- |
 | Palo Alto Networks | Technology | cybersecurity | $149.10 | -4.64% | -- | -- | -- | -- |
 | Apollo Global Management | Financials | fintech | $109.66 | -0.29% | -- | -- | -- | -- |
 | Newmont Corporation | Materials | commodities | $102.44 | +3.10% | -- | -- | -- | -- |
 | MP Materials | Materials | commoditiesdefence | $53.22 | +2.94% | -- | -- | -- | -- |
 | iShares Core US Aggregate Bond ETF | Fixed Income | -- | $98.54 | -0.01% | -- | -- | -- | -- |
 | iShares TIPS Bond ETF | Fixed Income | -- | $109.67 | -0.08% | -- | -- | -- | -- |